See more : Summit Industrial Income REIT (SMMCF) Income Statement Analysis – Financial Results
Complete financial analysis of Kyverna Therapeutics, Inc. (KYTX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Kyverna Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Liberty Media Acquisition Corporation (LMACU) Income Statement Analysis – Financial Results
- Teikoku Sen-i Co., Ltd. (3302.T) Income Statement Analysis – Financial Results
- China Bright Culture Group (1859.HK) Income Statement Analysis – Financial Results
- Sequoia Logística e Transportes S.A. (SEQL3.SA) Income Statement Analysis – Financial Results
- Thanachart Capital Public Company Limited (TCAP-R.BK) Income Statement Analysis – Financial Results
Kyverna Therapeutics, Inc. (KYTX)
About Kyverna Therapeutics, Inc.
Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial. The company is also developing KYV-201, an allogeneic CD19 CAR T-cell product candidate that is in preclinical stage to treat multiple autoimmune diseases. In addition, it is developing product candidates to treat other autoimmune diseases, such as inflammatory bowel disease that includes Crohn's disease and ulcerative colitis. Kyverna Therapeutics, Inc. has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product; and with Kite to research and develop programs for the treatment, diagnosis, and prevention of autoimmune, inflammatory, and allogeneic stem cell transplant inflammatory diseases. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.
| Metric | 2023 | 2022 | 2021 |
|---|---|---|---|
| Revenue | 0.00 | 7.03M | 5.66M |
| Cost of Revenue | 1.71M | 1.05M | 586.00K |
| Gross Profit | -1.71M | 5.97M | 5.07M |
| Gross Profit Ratio | 0.00% | 85.04% | 89.64% |
| Research & Development | 49.92M | 28.40M | 25.85M |
| General & Administrative | 12.48M | 8.01M | 6.15M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 |
| SG&A | 12.48M | 8.01M | 6.15M |
| Other Expenses | 0.00 | -9.00K | -2.00K |
| Operating Expenses | 62.41M | 36.41M | 32.00M |
| Cost & Expenses | 62.41M | 36.41M | 32.00M |
| Interest Income | 2.28M | 565.00K | 1.00K |
| Interest Expense | 187.00K | 65.00K | 3.00K |
| Depreciation & Amortization | 1.71M | 1.05M | 586.00K |
| EBITDA | -58.47M | -27.78M | -25.76M |
| EBITDA Ratio | 0.00% | -395.40% | -455.46% |
| Operating Income | -62.41M | -29.38M | -26.35M |
| Operating Income Ratio | 0.00% | -418.28% | -465.81% |
| Total Other Income/Expenses | 2.04M | 491.00K | -4.00K |
| Income Before Tax | -60.37M | -28.89M | -26.35M |
| Income Before Tax Ratio | 0.00% | -411.29% | -465.88% |
| Income Tax Expense | 0.00 | 56.00K | 1.00K |
| Net Income | -60.37M | -28.89M | -26.35M |
| Net Income Ratio | 0.00% | -411.29% | -465.88% |
| EPS | 0.00 | -1.12 | -1.02 |
| EPS Diluted | 0.00 | -1.12 | -1.02 |
| Weighted Avg Shares Out | 673.62M | 25.80M | 25.80M |
| Weighted Avg Shares Out (Dil) | 673.62M | 25.80M | 25.80M |
Investors Of KYTX Can Join The Securities Fraud Investigation Of Kyverna Therapeutics Inc Conducted By The Schall Law Firm
KYTX Investors Can Join The Securities Fraud Investigation Of Kyverna Therapeutics Inc By Schall Law Firm
First-in-Disease Use of Kyverna Therapeutics' KYV-101 in Patient With Severe Stiff-Person Syndrome Published in Proceedings of the National Academy of Sciences (PNAS)
Investors In KYTX Have The Chance To Participate In The Securities Fraud Probe Against Kyverna Therapeutics, Inc. With The Schall Law Firm
KYTX Investors Have Opportunity to Join Kyverna Therapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm
Kyverna Therapeutics and National Institutes of Health Co-Author Seminal Review on Cell Therapy for Autoimmunity in Nature Reviews Immunology
Kyverna Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results
Kyverna Therapeutics to attend the 2024 American Academy of Neurology (AAN) Annual Meeting in Denver, CO, With Data on KYV-101 in the Treatment of Patients with Neurological Autoimmune Diseases
First-in-Disease Use of Kyverna Therapeutics' KYV-101 in Patients With Progressive Multiple Sclerosis Published in Med
Kyverna Therapeutics Provides Business Update and Reports Full Year 2023 Financial Results
Source: https://incomestatements.info
Category: Stock Reports